Previous 10 | Next 10 |
Blueprint Medicines ( NASDAQ: BPMC ), the maker of systemic mastocytosis therapy Ayvakit, said Tuesday that it would file a supplemental new drug application to the FDA this year after the treatment reached main goals in a registration trial for patients with the non-advanced ...
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints PR Newswire -- AYVAKIT showed a superior mean change in total...
Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...
Blueprint Medicines Corporation (BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 A.M. ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer ...
Shares of oncology-focused Blueprint Medicines ( NASDAQ: BPMC ) surged ~13% in the morning hours Tuesday despite lower-than-expected financials for 2Q 2022 as management outlined plans to report data from a registration enabling trial for leading drug AYVAKIT in August. ...
Blueprint Medicines press release ( NASDAQ: BPMC ): Q2 GAAP EPS of -$2.68 misses by $0.45 . Revenue of $36.5M (+33.7% Y/Y) misses by $1.11M . As of June 30, 2022, cash, cash equivalents and investments were $947.2M, as compared to $1,034.6M ...
Blueprint Medicines Reports Second Quarter 2022 Results PR Newswire -- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 -- -- ...
Blueprint Medicines ( NASDAQ: BPMC ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$2.26 (-21.5% Y/Y) and the consensus Revenue Estimate is $37.61M (+37.8% Y/Y). Over the last 1 year, BPMC ...
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 PR Newswire CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference ...
Raymond James updated its list of analyst favorite stocks with a swap in the restaurant subsector. Analysts can only have one favorite idea among the stocks they cover rated Strong Buy or Outperform. Ruth's Hospitality Group ( NASDAQ: RUTH ) makes it onto the Analysts Cu...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective March 1, 2024, the C...
2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...